Should Three People be Allowed to Make a Baby?
By Arielle Duhaime-Ross,
Verge
| 06. 12. 2014
Untitled Document
For more than a decade, scientists have been developing a fertility technique that involves combining DNA from three parents to make a child. The technique, which has yet to be tested on humans, aims to help women who suffer from mitochondrial disease conceive a baby to which they are genetically related. But as the science inches closer to the human trial stage — some say that might happen in as little as two years — the scientific debate surrounding "three-parent babies" grows louder, and more polarized.
Just last week, for instance, a British scientific panel decided that the fertility technique is "not unsafe" for patients who suffer from mitochondrial disease. The decision hints that British government may soon amend legislation that currently bars the procedure, called mitochondrial replacement (MR), from entering human trials. Yet an American scientific panel reached a different conclusion in February when it decided that the science supporting MR was inconclusive and lacking. Thus, the first baby with three genetic parents will likely be British, and the two countries that are seriously considering...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...